丹酚酸C
| 中文名称 | 丹酚酸C |
|---|---|
| 中文同义词 | 丹酚酸C(标准品);丹参酚酸C;丹酚酸C;丹酚酸C对照品,;丹酚酸C(丹参酚酸C);(R,E)-3-(3,4-二羟基苯基)-2-((3-(2-(3,4-二羟基苯基)-7-羟基苯并呋喃-4-基)丙烯酰基)氧基)丙酸;标准品对照品】SALVIANOLIC ACID C;丹参酚酸C标准品,丹参酚酸C对照品 |
| 英文名称 | Salvianolicacid C |
| 英文同义词 | Salvianolicacid C;(alphaR)-alpha-[[(2E)-3-[2-(3,4-Dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxybenzenepropanoic acid;(2R)-3-(3,4-Dihydroxyphenyl)-2-({(2E)-3-[2-(3,4-dihydroxyphenyl)- 7-hydroxy-1-benzofuran-4-yl]-2-propenoyl}oxy)propanoic acid;Benzenepropanoic acid, α-[[(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-, (αR)-;Benzenepropanoic acid, a-[[(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-,(aR)-;(R,E)-3-(3,4-Dihydroxyphenyl)-2-((3-(2-(3,4-dihydroxyphenyl)-7-hydroxybenzofuran-4-yl)acryloyl)oxy)propanoic acid;(2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-(3,4-dihydroxypheny...;(2R)-3-(3,4-Dihydroxyphenyl)-2-({(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-1-benzofuran-4-yl]-2-propenoyl}oxy)propanoicaci |
| CAS号 | 115841-09-3 |
| 分子式 | C26H20O10 |
| 分子量 | 492.43 |
| EINECS号 | |
| 植物来源 | 丹参 |
| 相关类别 | 中药对照品;标准品;植物提取物;对照品;植提标准品;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;分析试剂标准品;标准品-中药标准品;标准品 -中药标准品;分析试剂-对照品;标准品，对照品;标准品-对照品;standardized herbal extract |
| Mol文件 | 115841-09-3.mol |
| 结构式 |  |
丹酚酸C 性质
| 沸点 | 844.2±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.570 |
| 储存条件 | under inert gas (nitrogen or Argon) at 2-8°C |
| 溶解度 | 溶于甲醇和水 |
| 形态 | 粉末 |
| 酸度系数(pKa) | 2.76±0.10(Predicted) |
| 颜色 | 粘黄色 |
| 主要应用 | 食品和饮料 |
| InChIKey | GCJWPRRNLSHTRY-QKKCHETFNA-N |
| SMILES | C(O)(=O)[C@H](OC(=O)/C=C/C1=C2C(=C(O)C=C1)OC(C1=CC=C(O)C(O)=C1)=C2)CC1=CC=C(O)C(O)=C1 |&1:3,r| |
|
CYP2C8 4.82 μM (Ki) |
CYP2J2 5.75 μM (Ki) |
Salvianolic acid C is a noncompetitive CYP2C8 inhibitor and a moderate mixed inhibitor of CYP2J2, with K i s of 4.82, 5.75 μM for CYP2C8 and CYP2J2, respectively. 1 and 5 μM Salvianolic acid C (SalC) could significantly inhibit the NO production induced by LPS. Salvianolic acid C decreases the expression of iNOS significantly. Salvianolic acid C inhibits LPS-induced TNF-α, IL-1β, IL-6 and IL-10 overproduction. Salvianolic acid C inhibits LPS-induced NF‑κB activation. Salvianolic acid C also increases the expression of Nrf2 and HO-1 in BV2 microglial cells.
Salvianolic acid C (20 mg/kg) treatment could significantly decrease the escape latency. In addition, SalC (10 and 20 mg/kg) treatment significantly increase the platform crossing number compared with the LPS model group. Systemic administration of Salvianolic acid C down regulates the brain TNF-α, IL-1β and IL-6 levels compared with the model group. The iNOS and COX-2 levels in rat brain cortex and hippocampus are higher than that in the control group, while Salvianolic acid C treatment significantly down regulates the cortex and hippocampus regions. Salvianolic acid C (5, 10 and 20 mg/kg) treatment dose-dependently increases the p-AMPK, Nrf2, HO-1 and NQO1 levels in rat brain cortex and hippocampus.
药理药效:具有一定抗氧化、保护脑组织细胞损伤、保护心脑血管系统和抗HIV作用。
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 存储类别 | 11 - 可燃固体 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/07/06 | S0922 | 丹酚酸C Salvianolic acid C | 115841-09-3 | 1mg | 573.13元 |
| 2026/07/06 | S0922 | 丹酚酸C Salvianolic acid C | 115841-09-3 | 5mg | 1711.71元 |